Article

Questioning the kidney-protective effects of tolvaptan: a testable hypothesis to revisit the current narrative

2026-07-16

Abstract excerpt

Tolvaptan is the only approved therapy for slowing disease progression in autosomal dominant polycystic kidney disease (ADPKD). Its use necessitates balancing kidney-protective effects against burdensome aquaretic side effects that limit long-term adherence. Both clinical and real-world data highlight that many eligible patients decline or discontinue therapy, complicating estimation of the true magnitude of kidne...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 73daeaf1-639a-5b42-a2d7-a152dd03624e
DOI: 10.12688/openreseurope.20428.2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Questioning the kidney-protective effects of tolvaptan: a testable hypothesis to revisit the current narrativeDOI 10.12688/openreseurope.20428.2Read

Tolvaptan in ADPKD Beyond Trials: Tolerability, Monitoring, and Real-World OutcomesSemantic proximity Read

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug Development.Semantic proximity Read

Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity Read

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.Semantic proximity Read

Methodological issues in clinical trials of polycystic kidney disease: a focused review.Semantic proximity Read

Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysisSemantic proximity Read

Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and TelmisartanSemantic proximity Read

Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary careSemantic proximity Read

Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.Semantic proximity Read

Effect of SGLT2 Inhibitors on CKD Progression and All-Cause Mortality: A Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

Four-Year Report on Renal Outcomes Following Elective Withdrawal of Long-Term RAAS Blockade in a Cohort of Patients with Otherwise Inexplicable New-Onset and Progressive Acute Kidney InjurySemantic proximity Read

A microsimulation-based framework for mitigating societal bias in primary care dataSemantic proximity Read